Home / Science / Leukemia Fight: "Double-Sided Tape" Boosts Immune Cells
Leukemia Fight: "Double-Sided Tape" Boosts Immune Cells
16 Mar
Summary
- Novel biomimetic platform enhances immune cell targeting of leukemia.
- The "FACE" technology bridges immune and cancer cells for better attack.
- This method showed significant efficacy in mouse models with reduced dosage.
Chinese scientists have developed a groundbreaking biomimetic platform, termed FACE (ferritin aggregation cell engager), designed to significantly improve leukemia treatment efficacy. This novel technology acts like a molecular "double-sided tape," enhancing the ability of engineered immune cells, known as CAR-T cells, to bind to and destroy leukemia cells. The FACE platform leverages the high expression of a protein called CD71, found on both leukemia and CAR-T cells, to bridge these cells and amplify the immune response.
This innovative approach offers a critical advantage by improving CAR-T cell recognition and eliminating leukemia cells more effectively, even when cancer cells evade detection by altering antigens. The FACE platform has demonstrated remarkable success in preclinical mouse models, achieving therapeutic effects with only one-fifth of the standard CAR-T cell dose and reducing side effects. Furthermore, a drug-loaded version of FACE enables direct chemotherapy delivery to cancer cells, boosting therapeutic outcomes against resistant leukemia subtypes.
The FACE platform is designed for seamless integration into existing CAR-T cell manufacturing processes, requiring no additional genetic engineering of the immune cells. Researchers have validated its broad applicability across multiple leukemia subtypes and treatment-resistant settings using both mouse models and human patient samples. This development holds substantial potential for clinical translation, offering a promising strategy to combat leukemia relapse and improve patient outcomes.
